🇺🇸 FDA
Patent

US 8334282

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61PA61P1/16A61P3/04

Quick answer

US patent 8334282 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P1/16, A61P3/04, A61P3/06, A61P3/10